Related references
Note: Only part of the references are listed.Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium
Steven G. DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Development of a biodosimeter for radiation triage using novel blood protein biomarker panels in humans and non-human primates
Robert P. Balog et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2020)
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma A Randomized Clinical Trial
Julie R. Park et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I-Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma
Kevin Campbell et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
FQC Dashboard: integrates FastQC results into a web-based, interactive, and extensible FASTQ quality control tool
Joseph Brown et al.
BIOINFORMATICS (2017)
Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131I-Metaiodobenzylguanidine (MIBG)
Megan Trieu et al.
PEDIATRIC BLOOD & CANCER (2016)
Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with 131I-mIBG, a Targeted Radionuclide
David A. Edmondson et al.
RADIATION RESEARCH (2016)
Phase I/II study of 131I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
S. G. DuBois et al.
BRITISH JOURNAL OF CANCER (2015)
Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois et al.
CLINICAL CANCER RESEARCH (2015)
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Yang Liao et al.
BIOINFORMATICS (2014)
A systematic review of 131 I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma
Jayne S. Wilson et al.
EUROPEAN JOURNAL OF CANCER (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
Steven G. DuBois et al.
CLINICAL CANCER RESEARCH (2012)
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms
Sabine Mueller et al.
CANCER LETTERS (2011)
Radioprotection by the histone deacetylase inhibitor phenylbutyrate
Alexandra C. Miller et al.
RADIATION AND ENVIRONMENTAL BIOPHYSICS (2011)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma
Steven G. DuBois et al.
NUCLEAR MEDICINE AND BIOLOGY (2008)
Transient sialoadenitis:: A complication of 131I-Metaiodobenzylguanidine therapy
Shakeel Modak et al.
PEDIATRIC BLOOD & CANCER (2008)
Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice
Stephen L. Brown et al.
RADIATION RESEARCH (2008)
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on Radiation Therapy Oncology Group protocol 92-02
Li Yan Khor et al.
CLINICAL CANCER RESEARCH (2007)
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma
Katherine K. Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Histone deacetylase inhibitors are potent radiation protectants
L Paoluzzi et al.
CANCER BIOLOGY & THERAPY (2004)
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma
SG DuBois et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Plasma Flt-3 ligand concentration correlated with radiation-induced bone marrow damage during local fractionated radiotherapy
A Huchet et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
R Edgar et al.
NUCLEIC ACIDS RESEARCH (2002)
Share Paper
